Animal models for viral infection and cell exhaustion

Current Opinion in HIV and AIDS

Volumn 9, Issue 5, 2014, Pages 492-499

  McGary, Colleen S ^a   Silvestri, Guido ^a   Paiardini, Mirko ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

animal models; humanized mice; nonhuman primates; programmed death 1; SIV

Indexed keywords

PROGRAMMED DEATH 1 RECEPTOR; ANTIRETROVIRUS AGENT;

EXHAUSTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PATHOGENESIS; PRIMATE; PRIORITY JOURNAL; RECEPTOR BLOCKING; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE EXHAUSTION; VIRUS LOAD; ANIMAL; CELL DEATH; DISEASE MODEL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MOUSE; PATHOPHYSIOLOGY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VIROLOGY;

ANIMALS; ANTI-RETROVIRAL AGENTS; CELL DEATH; DISEASE MODELS, ANIMAL; HIV INFECTIONS; HIV-1; MICE; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84906050404     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000093     Document Type: Review

References (72)

1. Wherry EJ. T cell exhaustion. Nature Immunol 2011; 12:492-499.
2. Wherry EJ, Ahmed R. Memory CD8 T-cell differentiation during viral infection. J Virol 2004; 78:5535-5545. (Pubitemid 38661640)
3. Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006; 439:682-687. (Pubitemid 43237609)
4. Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006; 443:350-354. (Pubitemid 44435155)
5. Jones RB, Ndhlovu LC, Barbour JD, et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. Journal Exp Med 2008; 205:2763-2779.
6. Kaufmann DE, Kavanagh DG, Pereyra F, et al. Upregulation of CTLA-4 by HIVspecific CD4\+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol 2007; 8:1246-1254. (Pubitemid 350011764)
7. Petrovas C, Casazza JP, Brenchley JM, et al. PD-1 is a regulator of virus-specific CD8\+ T cell survival in HIV infection. J Exp Med 2006; 203:2281-2292. (Pubitemid 44498363)
8. Petrovas C, Price DA, Mattapallil J, et al. SIV-specific CD8\+ T cells express high levels of PD1 and cytokines but have impaired proliferative capacity in acute and chronic SIVmac251 infection. Blood 2007; 110:928-936. (Pubitemid 47267431)
9. Trautmann L, Janbazian L, Chomont N, et al. Upregulation of PD-1 expression on HIV-specific CD8\+ T cells leads to reversible immune dysfunction. Nat Med 2006; 12:1198-1202. (Pubitemid 44527357)
10. Velu V, Kannanganat S, Ibegbu C, et al. Elevated expression levels of inhibitory receptor programmed death 1 on simian immunodeficiency virus-specific CD8 T cells during chronic infection but not after vaccination. J Virol 2007; 81:5819-5828. (Pubitemid 46847019)
11. Kuroda MJ, Schmitz JE, Charini WA, et al. Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys. J Immunol 1999; 162:5127-5133. (Pubitemid 29307114)
12. Hel Z, Nacsa J, Kelsall B, et al. Impairment of Gag-specific CD8(\+) T-cell function in mucosal and systemic compartments of simian immunodeficiency virus mac251-and simian-human immunodeficiency virus KU2-infected macaques. J Virol 2001; 75:11483-11495. (Pubitemid 33063240)
13. Vogel TU, Allen TM, Altman JD, Watkins DI. Functional impairment of simian immunodeficiency virus-specific CD8\+ T cells during the chronic phase of infection. J Virol 2001; 75:2458-2461. (Pubitemid 32147584)
14. Xiong Y, Luscher MA, Altman JD, et al. Simian immunodeficiency virus (SIV) infection of a rhesus macaque induces SIV-specific CD8(\+) T cells with a defect in effector function that is reversible on extended interleukin-2 incubation. J Virol 2001; 75:3028-3033. (Pubitemid 32185070)
15. Blackburn SD, Shin H, Haining WN, et al. Coregulation of CD8\+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 2009; 10:29-37.
16. Kinter AL, Godbout EJ, McNally JP, et al. The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol 2008; 181:6738-6746.
17. Salisch NC, Kaufmann DE, Awad AS, et al. Inhibitory TCR coreceptor PD-1 is a sensitive indicator of low-level replication of SIV and HIV-1. J Immunol 2010; 184:476-487.
18. Duraiswamy J, Ibegbu CC, Masopust D, et al. Phenotype, function, and gene expression profiles of programmed death-1(hi) CD8 T cells in healthy human adults. J Immunol 2011; 186:4200-4212.
19. Hong JJ, Amancha PK, Rogers K, et al. Re-evaluation of PD-1 expression by T cells as a marker for immune exhaustion during SIV infection. PLoS One 2013; 8:e60186.
20. Palmer BE, Boritz E, Blyveis N, Wilson CC. Discordance between frequency of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferonproducing CD4(\+) T cells and HIV-1-specific lymphoproliferation in HIV-1-infected subjects with active viral replication. J Virol 2002; 76:5925-5936. (Pubitemid 34556287)
21. Younes SA, Yassine-Diab B, Dumont AR, et al. HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4\+ T cells endowed with proliferative capacity. J Exp Med 2003; 198:1909-1922. (Pubitemid 38032123)
22. D'Souza M, Fontenot AP, Mack DG, et al. Programmed death 1 expression on HIV-specific CD4\+ T cells is driven by viral replication and associated with T cell dysfunction. J Immunol 2007; 179:1979-1987.
23. Kassu A, Marcus RA, D'Souza MB, et al. Regulation of virus-specific CD4\+ T cell function by multiple costimulatory receptors during chronic HIV infection. J Immunol 2010; 185:3007-3018.
24. Palmer BE, Neff CP, Lecureux J, et al. In vivo blockade of the PD-1 receptor suppresses HIV-1 viral loads and improves CD4\+ T cell levels in humanized mice. J Immunol 2013; 190:211-219.
25. Seung E, Dudek TE, Allen TM, et al. PD-1 blockade in chronically HIV-1-infected humanized mice suppresses viral loads. PLoS One 2013; 8:e77780.
26. Amancha PK, Hong JJ, Rogers K, et al. In vivo blockade of the programmed cell death-1 pathway using soluble recombinant PD-1-Fc enhances CD4\+ and CD8\+ T cell responses but has limited clinical benefit. J Immunol 2013; 191:6060-6070.
27. Velu V, Titanji K, Zhu B, et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 2009; 458:206-210.
28. Dyavar Shetty R, Velu V, Titanji K, et al. PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques. J Clin Invest 2012; 122:1712-1716.
29. Finnefrock AC, Tang A, Li F, et al. PD-1 blockade in rhesus macaques: Impact on chronic infection and prophylactic vaccination. J Immunol 2009; 182:980-987.
30. Nomaguchi M, Doi N, Kamada K, Adachi A. Species barrier of HIV-1 and its jumping by virus engineering. Rev Med Virol 2008; 18:261-275. (Pubitemid 352018849)
31. Shultz LD, Brehm MA, Garcia-Martinez JV, Greiner DL. Humanized mice for immune system investigation: Progress, promise and challenges. Nat Rev Immunol 2012; 12:786-798.
32. Berges BK, Wheat WH, Palmer BE, et al. HIV-1 infection and CD4 T cell depletion in the humanized Rag2-/-gamma c-/-(RAG-hu) mouse model. Retrovirology 2006; 3:76.
33. Brainard DM, Seung E, Frahm N, et al. Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virusinfected humanized BLT mice. J Virol 2009; 83:7305-7321.
34. Lan P, Tonomura N, Shimizu A, et al. Reconstitution of a functional human immune system in immunodeficient mice through combined human fetal thymus/liver and CD34\+ cell transplantation. Blood 2006; 108:487-492 (Pubitemid 44061346)
35. Tonomura N, Habiro K, Shimizu A, et al. Antigen-specific human T-cell responses and T cell-dependent production of human antibodies in a humanized mouse model. Blood 2008; 111:4293-4296.
36. Watanabe S, Terashima K, Ohta S, et al. Hematopoietic stem cell-engrafted NOD/SCID/IL2R gamma null mice develop human lymphoid systems and induce long-lasting HIV-1 infection with specific humoral immune responses. Blood 2007; 109:212-218. (Pubitemid 46070123)
37. Traggiai E, Chicha L, Mazzucchelli L, et al. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 2004; 304:104-107. (Pubitemid 38451466)
38. Berger R, Rotem-Yehudar R, Slama G, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008; 14:3044-3051.
39. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent antiprogrammed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28:3167-3175.
40. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369:134-144.
41. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J MedV 366 2012; 2443-2454.
42. Bhaskaran K, Hamouda O, Sannes M, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMAV 300 2008; 51-59. (Pubitemid 351920404)
43. Hogg R, Lima V, Sterne JAC, et al. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: A collaborative analysis of 14 cohort studies. Lancet 2008; 372:293-299.
44. Eisele E, Siliciano RF. Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity 2012; 37:377-388.
45. Richman DD, Margolis DM, Delaney M, et al. The challenge of finding a cure for HIV infection. Science 2009; 323:1304-1307.
46. Vargas-Inchaustegui DA, Xiao P, Hogg AE, et al. Immune targeting of PD-1(hi) expressing cells during and after antiretroviral therapy in SIV-infected rhesus macaques. Virology 2013; 447:274-284.
47. Mason S, editor (2013). Dual approach to HIV-1 cure: Activation of latency and restoration of exhausted virus-specific T cell function. 6th HIV Persistence Workshop; 5 December 2013; Miami, Florida.
48. Mkrtichyan M, Najjar YG, Raulfs EC, et al. B7-DC-Ig enhances vaccine effect by a novel mechanism dependent on PD-1 expression level on T cell subsets. J Immunol 2012; 189:2338-2347.
49. Larsson M, Shankar EM, Che KF, et al. Molecular signatures of T-cell inhibition in HIV-1 infection. Retrovirology 2013; 10:31.
50. Grohmann U, Orabona C, Fallarino F, et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002; 3:1097-1101. (Pubitemid 35363664)
51. Leng Q, Bentwich Z, Magen E, et al. CTLA-4 upregulation during HIV infection: Association with anergy and possible target for therapeutic intervention. AIDS 2002; 16:519-529. (Pubitemid 34218846)
52. Peritt D, Sesok-Pizzini DA, Schretzenmair R, et al. C1.7 antigen expression on CD8\+ T cells is activation dependent: Increased proportion of C1.7\+CD8\+ T cells in HIV-1-infected patients with progressing disease. J Immunol 1999; 162:7563-7568. (Pubitemid 29277738)
53. Price P, Keane N, Gray L, et al. CXCR4 or CCR5 tropism of human immunodeficiency virus type 1 isolates does not determine the immunological milieu in patients responding to antiretroviral therapy. Viral Immunol 2006; 19:734-740. (Pubitemid 46068066)
54. Sakhdari A, Mujib S, Vali B, et al. Tim-3 negatively regulates cytotoxicity in exhausted CD8\+ T cells in HIV infection. PLoS One 2012; 7:e40146.
55. Peretz Y, He Z, Shi Y, et al. CD160 and PD-1 co-expression on HIV-specific CD8 T cells defines a subset with advanced dysfunction. PLoS Pathog 2012; 8:e1002840.
56. Che KF, Shankar EM, Muthu S, et al. p38 mitogen-activated protein kinase/signal transducer and activator of transcription-3 pathway signaling regulates expression of inhibitory molecules in T cells activated by HIV-1-exposed dendritic cells. Mol Med 2012; 18:1169-1182.
57. Muthumani K, Choo AY, Shedlock DJ, et al. Human immunodeficiency virus type 1 Nef induces programmed death 1 expression through a p38 mitogenactivated protein kinase-dependent mechanism. J Virol 2008; 82:11536-11544.
58. Oestreich KJ, Yoon H, Ahmed R, Boss JM. NFATc1 regulates PD-1 expression upon T cell activation. J Immunol 2008; 181:4832-4839.
59. Jin HT, Anderson AC, Tan WG, et al. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc Natl Acad Sci USA 2010; 107:14733-14738.
60. Weiss L, Donkova-Petrini V, Caccavelli L, et al. Human immunodeficiency virus-driven expansion of CD4\+CD25\+ regulatory T cells, which suppress HIV-specific CD4 T-cell responses in HIV-infected patients. Blood 2004; 104:3249-3256. (Pubitemid 39507143)
61. Boasso A, Vaccari M, Hryniewicz A, et al. Regulatory T-cell markers, indoleamine 2,3-dioxygenase, and virus levels in spleen and gut during progressive simian immunodeficiency virus infection. J Virol 2007; 81:11593-11603. (Pubitemid 47623791)
62. Epple HJ, Loddenkemper C, Kunkel D, et al. Mucosal but not peripheral FOXP3\+ regulatory T cells are highly increased in untreated HIV infection and normalize after suppressive HAART. Blood 2006; 108:3072-3078.
63. Nilsson J, Boasso A, Velilla PA, et al. HIV-1-driven regulatory T-cell accumulation in lymphoid tissues is associated with disease progression in HIV/AIDS. Blood 2006; 108:3808-3817. (Pubitemid 44864563)
64. Nixon DF, Aandahl EM, Michaelsson J. CD4\+CD25\+ regulatory T cells in HIV infection. Microbes Infect 2005; 7:1063-1065. (Pubitemid 40982676)
65. Tsunemi S, Iwasaki T, Imado T, et al. Relationship of CD4\+CD25\+ regulatory T cells to immune status in HIV-infected patients. AIDS 2005; 19:879-886. (Pubitemid 40834930)
66. Cecchinato V, Tryniszewska E, Ma ZM, et al. Immune activation driven by CTLA-4 blockade augments viral replication at mucosal sites in simian immunodeficiency virus infection. J Immunol 2008; 180:5439-5447.
67. Dietze KK, Zelinskyy G, Gibbert K, et al. Transient depletion of regulatory T cells in transgenic mice reactivates virus-specific CD8\+ T cells and reduces chronic retroviral set points. Proc Natl Acad Sci USA 2011; 108:2420-2425.
68. Dietze KK, Zelinskyy G, Liu J, et al. Combining regulatory T cell depletion and inhibitory receptor blockade improves reactivation of exhausted virus-specific CD8\+ T cells and efficiently reduces chronic retroviral loads. PLoS Pathog 2013; 9:e1003798.
69. Brockman MA, Kwon DS, Tighe DP, et al. IL-10 is up-regulated in multiple cell types during viremic HIV infection and reversibly inhibits virus-specific T cells. Blood 2009; 114:346-356.
70. Clerici M, Wynn TA, Berzofsky JA, et al. Role of interleukin-10 in T helper cell dysfunction in asymptomatic individuals infected with the human immunodeficiency virus. J Clin Invest 1994; 93:768-775. (Pubitemid 24072820)
71. Kwon DS, Angin M, Hongo T, et al. CD4\+ CD25\+ regulatory T cells impair HIV-1-specific CD4 T cell responses by upregulating interleukin-10 production in monocytes. J Virol 2012; 86:6586-6594.
72. Porichis F, Hart MG, Zupkosky J, et al. Differential impact of PD-1 and/or interleukin-10 blockade on HIV-1-specific CD4 T cell and antigen-presenting cell functions. J Virol 2014; 88:2508-2518.